|
Abstract To observe the influence of Shengxuebao mixture for adjuvant treating pregnant women with iron deficiency anemia on their levels of mean red blood cell volume (MCV) and serum ferritin (SF) and their pregnancy outcomes. Methods: 120 pregnant women with iron deficiency anemia were divided into two groups from January 2017 to December 2018. The women in the control group were given Zulifei and the women in the observation group were treated with Shengxuebao mixture combined with Zulifei. The levels of blood related indexes, adverse drug reactions, and pregnancy outcomes of the women in the two groups after treating for 4 weeks were analyzed. Results: After treatment, the levels of hemoglobin (Hb), red blood cell count (RBC), MCV level, SF level, serum iron (SI) level, and ferritin saturation (TSAT) of women in the observation group were 124.36±6.36 g/L, 3.94±0.45 ×1012/L, 97.21±11.41 fL, 20.77±3.26 g/L, (1.32±4.11 mol/L, and 31.96±5.68 %, which were significnat higher than those of women in the control group (P<0.05). The incidences of adverse reactions, postpartum hemorrhage, fetal distress, preterm birth, and low birth weight of women in the observation group were 8.3%, 1.7%, 5.0%, 2.3%, and 1.7%, which had no significant different from those of women in the control group (P>0.05). Conclusion: Shengxuebao mixture on for adjuvant therapy pregnant women with iron deficiency anemia can effectively improve their blood related indexes, increase therapeutic effect, and has little adverse effect on pregnancy outcomes with high safety.
|
